sinc
vaccin
document
edward
jenner
becom
success
mean
prevent
infecti
diseas
save
million
live
everi
year
applic
vaccin
current
limit
prevent
infecti
diseas
vaccin
pipelin
includ
amongst
other
therapeut
vaccin
allergi
cancer
alzheim
diseas
modern
biotechnolog
enorm
impact
current
vaccin
develop
elucid
molecular
structur
pathogen
tremend
progress
made
immunolog
well
develop
proteom
bioinformat
led
identif
protect
antigen
way
deliv
togeth
technolog
advanc
caus
move
empir
vaccin
develop
ration
approach
develop
effect
safe
vaccin
addit
modern
methodolog
may
provid
simpler
cheaper
product
process
select
vaccin
compon
although
vaccin
resembl
biopharmaceut
therapeut
protein
aspect
sever
import
differ
tabl
uniqu
featur
vaccin
includ
low
dose
frequenc
administr
wide
differ
vaccin
categori
tabl
also
target
group
patient
basic
everi
human
planet
emphasi
young
healthi
children
differ
huge
impact
requir
vaccin
admiss
market
releas
vaccin
batch
put
safeti
requir
par
efficaci
follow
section
immunolog
principl
import
vaccin
design
summar
subsequ
vaccin
categori
discuss
includ
current
develop
especi
field
therapeut
cancer
vaccin
intent
provid
comprehens
review
rather
explain
current
approach
vaccin
develop
illustr
approach
repres
exampl
rout
administr
discuss
separ
section
last
section
pharmaceut
aspect
vaccin
includ
issu
relat
product
formul
character
storag
dealt
reaction
infect
human
immun
system
launch
seri
immunolog
respons
goal
elimin
pathogen
innat
immun
cell
first
respond
attempt
clear
pathogen
phagocytosi
andor
lysi
pathogen
develop
strategi
evad
innat
immun
respons
vertebr
capabl
elicit
highli
specif
respons
virtu
adapt
immun
system
adapt
immun
system
gener
humor
immun
cellmedi
immun
see
fig
tabl
antibodi
produc
bcell
typic
repres
humor
immun
antibodi
belong
one
four
differ
immunoglobulin
class
igm
igg
iga
ige
cf
chap
antibodi
abl
prevent
infect
diseas
sever
mechan
bind
antibodi
cover
pathogen
fc
constant
fragment
rear
end
immunoglobulin
phagocyt
cell
macrophag
antibodi
effect
mani
infecti
microorgan
may
limit
valu
pathogen
occupi
intracellular
nich
intracellular
bacteria
parasit
easili
reach
antibodi
case
cellmedi
immun
requir
clear
infect
cell
tcell
major
repres
cellmedi
immun
clear
infect
follow
mechan
cytotox
tlymphocyt
ctl
also
call
cytotox
tcell
react
target
cell
kill
releas
cytolyt
protein
like
perforin
thelper
cell
see
activ
macrophag
allow
kill
intracellular
pathogen
contrast
innat
respons
adapt
immun
respons
specif
invad
pathogen
fig
adapt
immun
system
compris
bcell
tcell
wide
rang
specif
owe
uniqu
composit
bcell
receptor
bcr
tcell
receptor
tcr
infect
innat
immun
system
instruct
band
tcell
bcr
tcr
specif
invad
pathogen
prolifer
gain
effector
function
infect
clear
band
tcell
obsolet
mani
die
apoptosi
antibodi
produc
bcell
howev
persist
circul
extend
period
time
moreov
band
tcell
resist
apop
tosi
maintain
mani
year
memori
band
tcell
contrast
naiv
counterpart
memori
cell
rapidli
activ
clonal
expand
reencount
pathogen
later
occas
therefor
unlik
primari
respons
respons
repeat
infect
fast
usual
suffici
strong
prevent
reoccurr
diseas
fig
vaccin
exploit
format
immunolog
memori
adapt
immun
system
principl
vaccin
mimick
infect
way
natur
specif
defens
mechan
host
pathogen
activ
immunolog
memori
establish
host
remain
free
diseas
normal
result
natur
infect
fig
effectu
administr
antigen
compon
consist
deriv
relat
pathogen
immun
respons
highli
specif
discrimin
pathogen
speci
often
also
differ
strain
within
one
speci
eg
strain
meningococci
polioviru
influenza
viru
albeit
sometim
hurdl
vaccin
develop
high
specif
immun
system
allow
almost
perfect
balanc
respons
foreign
antigen
toler
selfantigen
wherea
prophylact
vaccin
aim
immunolog
memori
primari
goal
therapeut
vaccin
usual
induct
potent
effector
respons
rather
memori
next
paragraph
discuss
immunolog
principl
lead
effector
memori
respons
gener
immun
respons
vaccin
follow
sever
distinct
step
ultim
lead
potent
effector
respons
longlast
memori
administr
vaccin
first
step
uptak
profession
antigenpres
cell
apc
site
applic
apc
abl
shuttl
vaccin
compon
secondari
lymphoid
organ
present
antigen
tand
blymphocyt
whichund
right
conditionsresult
activ
lymphocyt
simplifi
process
illustr
fig
describ
detail
success
step
lead
immun
respons
particular
step
relev
design
vaccin
everi
immun
reaction
pathogen
vaccin
start
activ
innat
immun
system
although
innat
respons
lead
immunolog
memori
instrument
activ
educ
adapt
immun
system
import
constitu
innat
immun
system
apc
like
macrophag
dendrit
cell
dc
resid
tissu
continu
endocytos
extracellular
materi
sampl
environ
potenti
harm
materi
distinguish
harm
innocu
substanc
apc
equip
pattern
recognit
receptor
prr
allow
detect
conserv
microbi
viral
structur
call
pathogenassoci
molecular
pattern
pamp
kawai
akira
prr
activ
induc
matur
program
switch
apc
antigen
sampl
antigen
present
mode
critic
role
intermedi
lymphocyt
activ
prr
activ
induc
express
mhc
class
mhci
mhc
class
ii
mhcii
molecul
increas
apc
capac
present
antigen
tcell
moreov
apc
gain
express
chemokin
receptor
eg
allow
migrat
secondari
lymphoid
tissu
final
prr
stimul
induc
upregul
costimulatori
molecul
proinflammatori
cytokin
provid
import
activ
signal
tcell
antigen
present
prr
activ
essenti
step
vaccin
process
therefor
import
consid
design
vaccin
live
attenu
inactiv
vaccin
natur
contain
pamp
activ
prr
howev
subunit
vaccin
may
lack
pamp
may
requir
addit
adjuv
see
section
formul
peripher
lymphoid
organ
primari
meet
place
cell
innat
immun
system
apc
cell
adapt
immun
system
tcell
bcell
wherea
apc
distribut
throughout
peripher
tissu
tand
bcell
primarili
locat
secondari
lymphoid
organ
lymph
node
spleen
peyer
patch
import
reason
although
human
bodi
harbor
larg
number
lymphocyt
ca
tand
bcell
tcr
bcr
specif
antigen
interest
concentr
lymphocyt
secondari
lymphoid
organ
apc
present
antigen
chanc
antigen
specif
tand
bcell
encount
cognat
antigen
increas
upon
interact
apc
antigen
specif
tcell
bcell
activ
provid
acquir
appropri
signal
first
signal
antigen
present
allow
select
antigen
specif
band
tcell
bcell
tcell
recogn
antigen
differ
way
bcell
recogn
antigen
nativ
form
bcr
allow
direct
interact
antigen
therefor
bcell
antigen
requir
major
process
fact
bcell
take
antigen
small
enough
drain
lymph
node
without
help
apc
shuttl
larger
antigen
lymphoid
tissu
nativ
form
apc
express
receptor
allow
present
intact
antigen
bcell
batista
harwood
antigen
abl
directli
stimul
antibodi
product
bcell
without
tcell
involv
thymusindepend
antigen
includ
certain
linear
antigen
readili
degrad
bodi
repeat
determin
bacteri
polysaccharid
thymusindepend
antigen
induc
immunolog
memori
therefor
less
interest
vaccin
standpoint
possibl
howev
render
antigen
thymu
depend
chemic
coupl
protein
carrier
see
section
bcell
tcell
activ
polysaccharid
vaccin
tcell
unabl
directli
interact
antigen
depend
apc
process
antigen
peptid
fragment
tcell
epitop
present
tcell
context
mhci
tcell
mhcii
molecul
tcell
apc
surfac
whether
antigen
present
mhci
mhcii
molecul
depend
intracellular
locat
antigen
process
exogen
antigen
acquir
endocytosi
undergo
limit
proteolysi
endosom
associ
mhcii
molecul
fig
load
mhcii
molecul
return
surfac
overview
step
lead
immun
administr
vaccin
upon
subcutan
intramuscular
administr
vaccin
compon
taken
phagocyt
cell
macrophag
dendrit
cell
dc
resid
peripher
tissu
express
pattern
recognit
receptor
prr
recogn
pathogenassoci
molecular
pattern
pamp
profession
antigenpres
cell
apc
taken
antigen
becom
activ
start
migrat
toward
nearbi
lymph
node
insid
lymph
node
antigen
process
apc
present
lymphocyt
recogn
antigen
receiv
appropri
costimulatori
signal
becom
activ
antigenspecif
band
tcell
clonal
expand
produc
multipl
progenitor
recogn
antigen
addit
memori
band
tcell
form
provid
longterm
sometim
lifelong
protect
infect
pathogen
interact
thelper
cell
endogen
antigen
viral
mutat
protein
produc
host
cell
gener
proteasom
process
cytosol
result
peptid
associ
mhci
endoplasmat
reticulum
interact
cytotox
tcell
fig
differ
antigen
present
pathway
consequ
vaccin
design
tcell
recogn
process
antigen
fragment
tcell
respons
reli
continu
epitop
linear
peptid
sequenc
usual
consist
ten
amino
acid
residu
protein
see
fig
contrast
bcell
epitop
discontinu
epitop
compris
amino
acid
residu
sometim
far
apart
primari
sequenc
brought
togeth
uniqu
fold
protein
see
fig
antibodi
recognit
bcell
epitop
whether
continu
discontinu
usual
depend
conform
threedimension
structur
antigen
vaccin
aim
induc
high
level
neutral
antibodi
instanc
diphtheria
tetanu
vaccin
one
take
great
care
antigen
remain
nativ
form
vaccin
induc
ctl
respons
eg
viru
vaccin
cancer
vaccin
necessarili
requir
antigen
nativ
form
antigen
degrad
present
anyway
major
challeng
type
vaccin
howev
mhci
present
requir
antigen
enter
cytosol
rather
endosom
compart
apc
see
fig
profession
apc
especi
dc
capac
transfer
exogen
acquir
antigen
endosom
compart
mhci
process
pathway
process
refer
crosspresent
next
tcr
stimul
peptid
load
mhci
mhcii
molecul
second
signal
tcell
requir
costimul
via
interact
accessori
costimulatori
molecul
apc
fig
cellcel
interact
essenti
proper
stimul
lymphocyt
without
accessori
signal
antigenspecif
tcell
prolifer
may
becom
anerg
ie
acquir
state
unrespons
costimulatori
molecul
upregul
apc
prr
stimul
signal
function
addit
safeti
check
prevent
unwant
immun
respons
selfantigen
tcell
receiv
tcr
stimul
costimul
becom
activ
clonal
expand
gener
multipl
progenitor
recogn
antigen
contrast
tcell
also
receiv
coinhibitori
signal
apc
eg
activ
signal
reduc
tcell
activ
provid
neg
control
mechan
uncontrol
unwant
tcell
respons
clonal
expans
tcell
receiv
cytokin
signal
influenc
fate
signal
cytokin
promot
tcell
prolifer
also
affect
effector
function
see
fig
instanc
interleukin
type
interferon
ifn
cytokin
essenti
develop
ctl
lack
cytokin
result
reduc
prolifer
ctl
reduc
capac
kill
target
cell
especi
thelper
cell
cytokin
signal
prime
crucial
thelper
cell
variou
effector
function
instanc
presenc
cytokin
type
ifn
tcell
develop
thelper
cell
cell
produc
cytokin
tumor
necrosi
factor
alfa
potenti
effector
function
phagocyt
increas
inflamm
therefor
induct
memori
cell
major
goal
vaccin
aim
protect
intracellular
pathogen
thelper
cell
develop
influenc
signal
cell
produc
anoth
set
cytokin
prevent
differenti
support
bcell
prolifer
differenti
cell
therefor
associ
increas
humor
respons
howev
cytokin
produc
cell
link
ige
product
bcell
reduc
number
memori
cell
becom
import
focu
design
vaccin
aim
reduc
allerg
respons
next
cell
variou
thelper
subset
identifi
uniqu
function
properti
cell
develop
tcell
receiv
transform
growth
factor
beta
signal
produc
cytokin
support
defens
mucos
surfac
also
link
inflammatori
diseas
inflammatori
bowel
diseas
psoriasi
regulatori
tcell
treg
subset
tcell
play
import
role
limit
inflamm
secret
antiinflammatori
cytokin
induct
treg
may
interest
vaccin
aim
reduc
inflamm
autoimmun
diseas
one
particular
subset
thcell
devot
provid
help
bcell
socal
tfollicular
helper
cell
tfh
influenc
tfh
upregul
molecul
cxc
chemokin
receptor
type
allow
migrat
bcell
zone
tfh
interact
bcell
present
cognat
antigen
mhcii
molecul
bcell
receiv
costimulatori
signal
tfh
abl
gener
highaffin
igg
antibodi
matur
memori
bcell
consequ
vaccin
design
vaccin
aim
gener
bcell
memori
need
contain
bcell
tcell
epitop
one
entiti
instanc
polysaccharid
deriv
haemophilu
influenza
type
b
neisseria
meningitidi
streptococcu
pneumonia
target
neutral
antibodi
requir
conju
vaccin
classifi
base
whether
aim
prevent
prophylact
cure
therapeut
diseas
type
diseas
treat
infecti
diseas
allergi
autoimmun
diseas
cancer
etc
antigen
sourc
use
vaccin
eg
whole
pathogen
subunit
peptid
nucleic
acid
illustr
fig
first
discuss
vaccin
categori
base
antigen
sourc
next
current
develop
therapeut
vaccin
cancer
diseas
highlight
tradit
vaccin
origin
virus
bacteria
divid
vaccin
consist
live
attenu
pathogen
nonliv
inactiv
pathogen
case
antigen
convey
immun
known
specif
subunit
deriv
pathogen
protein
polysaccharid
formul
vaccin
nowaday
subunit
vaccin
also
made
recombinantli
case
protein
chemic
conjug
carrier
protein
case
polysaccharid
enhanc
immun
respons
antigen
compon
moreov
current
knowledg
immun
recognit
band
tcell
epitop
identifi
synthet
made
final
nucleic
acid
form
separ
class
antigen
sourc
dna
rna
encod
antigen
interest
transfect
host
cell
enabl
endogen
product
present
protein
antigen
overview
variou
categori
vaccin
exampl
thereof
given
tabl
detail
section
introduct
recombin
dna
rdna
technolog
live
vaccin
made
attenu
virul
microorgan
serial
passag
select
mutant
strain
reduc
virul
toxic
exampl
vaccin
strain
current
vaccin
oral
polio
vaccin
measlesmumpsrubella
mmr
combin
vaccin
yellow
fever
vaccin
tuberculosi
vaccin
consist
bacil
bcg
altern
approach
chemic
mutagenesi
instanc
treat
salmonella
typhi
nitrosoguanidin
mutant
strain
lack
enzym
respons
virul
isol
germani
fuer
live
attenu
vaccin
advantag
administr
may
replic
host
similar
pathogen
counterpart
confront
host
larger
sustain
dose
antigen
pamp
mean
low
dose
requir
gener
vaccin
give
longlast
humor
cellmedi
immun
live
attenu
vaccin
also
drawback
live
viral
vaccin
bear
risk
revert
virul
form
although
unlik
attenu
seed
strain
contain
sever
mutat
nevertheless
diseas
viral
hepat
aid
cancer
drawback
make
use
tradit
live
vaccin
virtual
unthink
furthermor
import
recogn
immun
immunedefici
children
immunocompromis
adult
live
organ
lead
seriou
complic
instanc
child
tcell
defici
may
becom
overwhelm
bcg
die
similarli
patient
use
certain
immunosuppress
drug
eg
cyclosporin
methotrex
vaccin
live
attenu
vaccin
emerg
insight
molecular
pathogenesi
mani
infecti
diseas
make
possibl
attenu
microorgan
effici
nowaday
make
multipl
delet
risk
revers
virul
state
product
administr
virtual
elimin
prerequisit
attenu
genet
engin
factor
respons
virul
life
cycl
pathogen
known
detail
also
obviou
protect
antigen
epitop
must
known
attenu
must
result
reduc
immunogen
exampl
improv
live
vaccin
obtain
homolog
genet
engin
oral
cholera
vaccin
vaxchora
effect
cholera
vaccin
induc
local
humor
respons
order
prevent
colon
small
intestin
initi
trial
vibrio
cholera
cholera
toxin
ct
mutant
caus
mild
diarrhea
thought
caus
express
accessori
toxin
natur
mutant
isol
neg
toxin
next
ct
detoxifi
rdna
technolog
result
vaccin
strain
call
cvd
well
toler
challeng
experi
adult
volunt
show
protect
levin
et
al
garcia
et
al
genet
attenu
live
vaccin
gener
drawback
mention
paragraph
classic
attenu
live
vaccin
reason
surpris
homolog
engin
mainli
restrict
pathogen
use
start
materi
product
subunit
vaccin
see
section
subunit
vaccin
way
improv
safeti
efficaci
vaccin
use
live
avirul
attenu
bacteria
virus
carrier
express
protect
antigen
pathogen
see
tabl
exampl
live
vector
vaccin
creat
recombin
technolog
wherein
one
gene
vector
organ
replac
one
protect
gene
pathogen
administr
live
vector
vaccin
result
effici
prolong
express
antigenencod
gene
either
vaccin
individu
cell
vector
organ
eg
case
bacteri
vector
experi
acquir
vaccinia
viru
use
principl
schemat
shown
fig
advantag
vaccinia
viru
vector
includ
proven
safeti
human
smallpox
vaccin
possibl
multipl
immunogen
express
eas
product
rel
heat
resist
variou
possibl
administr
rout
multitud
live
recombin
vaccinia
vaccin
viral
tumor
antigen
construct
sever
test
clinic
njuguna
et
al
buchbind
et
al
payn
et
al
demonstr
product
gene
code
viral
envelop
protein
correctli
process
insert
plasma
membran
infect
cell
adenovirus
also
use
vaccin
vector
see
also
chap
adenovirus
sever
characterist
make
suitabl
vaccin
vector
infect
broad
rang
divid
nondivid
mammalian
cell
expand
possibl
select
product
cell
line
transgen
express
gener
high
increas
use
heterolog
promot
sequenc
adenoviru
vector
mostli
replic
defici
integr
genom
chromosom
host
cell
make
vector
safe
use
upon
parenter
administr
adenoviru
vector
induc
strong
immun
evok
humor
cellular
respons
express
antigen
number
clinic
trial
human
chimpanze
adenoviru
vector
express
antigen
ebola
viru
human
immunodefici
viru
hiv
sever
acut
respiratori
syndrom
sar
perform
cohen
frahm
major
limit
use
live
vector
vaccin
preval
preexist
immun
vector
could
neutral
vaccin
immun
system
prime
preexist
immun
describ
adenovir
vector
preval
neutral
antibodi
high
total
popul
use
human
nonhuman
eg
chimpanze
strain
low
preval
preexist
immun
live
vector
therefor
recommend
ahi
et
al
wong
et
al
earli
approach
prepar
vaccin
inactiv
whole
bacteria
virus
number
chemic
reagent
eg
formaldehyd
glutaraldehyd
heat
commonli
use
inactiv
exampl
inactiv
vaccin
whole
cell
pertussi
cholera
typhoid
fever
polio
vaccin
inactiv
may
result
loss
relev
epitop
due
coval
chang
partial
unfold
antigen
also
sinc
vaccin
replic
vivo
often
higher
dose
need
induc
protect
compar
live
attenu
vaccin
may
increas
price
given
complex
batchtobatch
variabl
vaccin
consist
inactiv
whole
pathogen
use
welldefin
antigen
subunit
pathogen
desir
subunit
antigen
protein
polysaccharid
directli
purifi
pathogen
recombinantli
produc
protein
antigen
synthet
peptid
bacteria
corynebacterium
diphtheria
clostridium
tetani
form
toxin
antibodymedi
immun
toxin
main
protect
mechan
advers
effect
infect
bacteria
toxin
protein
inactiv
formaldehyd
inclus
vaccin
immunogen
toxoid
rel
low
improv
adsorpt
toxoid
colloid
aluminum
salt
combin
antigen
adjuv
still
use
combin
vaccin
bacteri
capsular
polysaccharid
consist
pathogenspecif
multipl
repeat
carbohydr
epitop
isol
cultur
pathogen
speci
plain
capsular
polysaccharid
thymusindepend
antigen
poorli
immunogen
infant
show
poor
immunolog
memori
appli
older
children
adult
immunogen
polysaccharid
highli
increas
chemic
coupl
carrier
protein
contain
tcell
epitop
coupl
make
tcell
depend
due
particip
thcell
activ
respons
carrier
exampl
polysaccharid
conjug
vaccin
includ
meningococc
type
c
pneumococc
haemophilu
influenza
type
b
hib
polysaccharid
vaccin
includ
mani
nation
immun
program
rel
frequent
occurr
side
effect
whole
cell
pertussi
vaccin
main
reason
develop
subunit
pertussi
vaccin
develop
acellular
pertussi
vaccin
exemplifi
better
insight
factor
import
pathogenesi
immunogen
lead
improv
vaccin
conceiv
subunit
vaccin
consist
limit
number
purifi
immunogen
compon
devoid
toxic
bacteri
lp
would
significantli
reduc
undesir
effect
current
licens
acellular
pertussi
vaccin
contain
one
four
protein
antigen
although
vaccin
effect
prevent
regular
epidem
whoop
cough
mani
western
countri
shortliv
immun
vaccin
induc
select
circul
strain
resist
prime
immun
system
may
contribut
therefor
attempt
made
improv
vaccin
scheme
develop
new
pertussi
vaccin
improv
yield
facilit
product
andor
improv
safeti
proteinbas
vaccin
protein
antigen
nowaday
often
produc
recombinantli
ie
express
host
cell
safe
handl
allow
high
express
level
heterolog
host
use
express
protein
antigen
includ
yeast
bacteria
insect
cell
plant
cell
mammalian
cell
line
hepat
b
surfac
antigen
hbsag
previous
obtain
plasma
infect
individu
express
baker
yeast
saccharomyc
cerevisia
vanlandschoot
et
al
mammalian
cell
chines
hamster
ovari
cell
raz
et
al
transform
host
cell
plasmid
contain
hbsagencod
gene
express
system
yield
hbsag
particl
also
call
viruslik
particl
vlp
structur
ident
nativ
viru
advantag
safeti
consist
qualiti
high
yield
yeastderiv
vaccin
becom
avail
worldwid
appear
safe
efficaci
classic
plasmaderiv
vaccin
two
human
papillomaviru
hpv
vaccin
current
market
produc
recombin
protein
like
hbsag
assembl
spontan
viruslik
particl
antigen
gardasil
quadrival
hpv
vaccin
produc
yeast
wherea
antigen
bival
vaccin
cervarix
produc
insect
cell
identif
protect
epitop
possibl
incorpor
correspond
peptid
sequenc
genet
fusion
carrier
protein
hbsag
hepat
b
core
antigen
franci
larch
peptideencod
dna
sequenc
synthes
insert
carrier
protein
gene
exampl
recombin
peptid
approach
malaria
vaccin
base
repeat
asnalaasnpro
sequenc
plasmodium
falciparum
surfac
antigen
gene
encod
peptid
fuse
hbsag
gene
fusion
product
express
yeast
cell
vreden
et
al
clinic
trial
candid
malaria
vaccin
demonstr
moder
efficaci
children
infant
africa
rt
clinic
trial
partnership
genet
fusion
peptid
protein
offer
possibl
produc
protect
epitop
toxic
antigen
deriv
pathogen
speci
part
nontox
protein
express
harmless
speci
furthermor
uniform
product
obtain
comparison
variabl
chemic
conjug
see
section
synthet
peptid
vaccin
principl
vaccin
could
consist
relev
epitop
instead
intact
pathogen
protein
peptid
epitop
small
enough
produc
synthet
peptidebas
vaccin
would
much
better
defin
tradit
vaccin
make
concept
peptid
vaccin
attract
howev
turn
difficult
develop
vaccin
today
licens
peptidebas
vaccin
avail
yet
nevertheless
import
progress
made
synthet
peptid
vaccin
enter
clinic
eg
immunotherapi
cancer
melief
van
der
burg
van
poelgeest
et
al
understand
complex
peptid
vaccin
one
distinguish
differ
type
epitop
epitop
recogn
antibodi
bcell
often
conform
depend
see
section
immunolog
principl
van
regenmortel
reason
difficult
identifi
accur
synthes
correct
conform
manipul
antigen
digest
clone
part
gene
often
affect
bcell
epitop
integr
accur
way
identifi
epitop
elucid
crystal
structur
antigenantibodi
complex
difficult
time
consum
although
crystallographi
reveal
molecular
interact
unsurpass
detail
molecular
complex
like
much
dynam
solut
epitop
identifi
synthes
function
peptid
proven
difficult
well
peptid
need
conform
restrain
achiev
cycliz
peptid
oomen
et
al
use
scaffold
synthes
complex
peptid
structur
timmerman
et
al
regard
conform
tcell
epitop
less
demand
present
natur
process
peptid
apc
tcell
result
tcell
epitop
linear
discern
epitop
amino
acid
residu
mhc
class
restrict
epitop
amino
acid
residu
mhc
class
ii
restrict
main
requir
fit
bind
groov
mhc
molecul
high
enough
affin
studi
peptidebas
cancer
vaccin
shown
contain
epitop
order
elicit
protect
immun
respons
furthermor
minim
peptid
extern
load
mhc
molecul
cell
shown
induc
less
robust
respons
longer
peptid
requir
intracellular
process
uptak
dc
anoth
point
consid
variabl
repertoir
mhc
molecul
patient
popul
impli
tcell
epitopebas
peptid
vaccin
contain
sever
tcell
epitop
order
effect
major
vaccin
popul
follow
concept
clinic
trial
overlap
long
peptid
vaccin
shown
promis
result
immunotherapi
patient
hpvinduc
malign
melief
van
der
burg
immun
nucleic
acid
vaccin
involv
administr
genet
materi
plasmid
dna
messeng
rna
mrna
encod
desir
antigen
encod
antigen
express
host
cell
immun
respons
express
antigen
rais
nucleic
acid
vaccin
offer
safeti
subunit
vaccin
advantag
live
recombin
vaccin
induc
strong
ctl
respons
encod
antigen
addit
bacteri
plasmid
ideal
activ
innat
immun
express
mani
phagocyt
cell
recogn
unmethyl
bacteri
dna
see
section
adjuv
main
disadvantag
nucleic
acid
immun
poor
immunogen
man
therefor
often
requir
like
subunit
vaccin
adjuv
deliveri
system
boost
immun
respons
dnaencod
antigen
nevertheless
dna
proven
effect
use
combin
protein
antigen
heterolog
dnaprim
proteinboost
strategi
longterm
safeti
nucleic
acid
vaccin
remain
establish
main
pro
con
nucleic
acid
vaccin
list
tabl
exampl
dna
vaccin
test
clinic
trial
compris
plasmid
encod
antigen
malaria
antigen
recent
year
mrna
vaccin
gain
increas
attent
mainli
excel
safeti
profil
transient
nonintegr
protein
express
enhanc
immunogen
compar
plasmid
dna
vaccin
mrna
vaccin
typic
appli
oncolog
express
mixtur
tumor
antigen
also
appli
person
vaccin
initi
mrnabas
vaccin
cope
stabil
problem
poor
express
level
enhanc
immunogen
prolong
protein
express
mrna
either
chemic
modifi
backbon
nucleosid
modif
sequenc
optim
formul
nanocarri
eg
protamin
nanoparticl
modif
result
slower
degrad
enhanc
immun
activ
primarili
signal
optim
mrna
vaccin
shown
elicit
strong
balanc
immun
respons
anim
model
technolog
current
test
clinic
trial
eg
treatment
prostat
cancer
kubler
et
al
nonsmal
cell
lung
carcinoma
sebastian
et
al
demonstr
antigenspecif
immun
respons
patient
one
drawback
mrnabas
vaccin
transient
natur
often
lead
short
antigen
express
time
unfavor
proper
immun
activ
circumv
make
use
selfamplifi
rna
base
alphaviru
replic
machineri
four
alphaviru
gene
respons
rna
replic
coexpress
gene
interest
encod
desir
antigen
fig
transfect
singl
rna
construct
cell
lead
prolong
enhanc
antigen
express
sinc
nucleic
acid
easili
enter
cell
requir
intracellular
deliveri
intact
form
activ
therapeut
applic
biomacromolecul
requir
sophist
deliveri
method
system
detail
descript
nucleic
acid
deliveri
system
found
chap
gene
therapi
vaccin
purpos
nake
nucleic
acid
ie
without
deliveri
system
administ
anim
human
via
intramuscular
inject
favor
properti
muscl
cell
dna
express
probabl
due
rel
low
turnov
rate
prevent
plasmid
dna
rapidli
dispers
divid
cell
intracellular
uptak
dna
encod
protein
express
surfac
host
cell
singl
inject
express
last
year
howev
use
nake
dna
vaccin
requir
high
dose
like
poor
deliveri
far
shown
poor
immunogen
human
trial
physic
method
dna
deliveri
use
well
includ
ballist
approach
use
gene
gun
inject
dnacoat
gold
nanoparticl
epidermi
jetinjector
electropor
dna
tattoo
samuel
et
al
deliveri
nucleic
acid
lipid
polymer
nanocarri
increas
cellular
uptak
immun
activ
nanocarri
protect
nucleic
acid
prematur
degrad
enhanc
cellular
uptak
profession
apc
besid
synthet
nanocarri
virus
use
vector
well
distinct
made
replic
virus
replic
incompet
exampl
latter
fowlpox
canarypox
virus
infect
mammalian
cell
unabl
replic
canarypox
viru
express
clinic
test
part
heterolog
primeboost
prophylact
hiv
vaccin
oconnel
et
al
besid
virus
bacteria
replic
insid
cell
also
use
deliv
plasmid
dna
host
cell
express
pathogenderiv
antigen
attenu
strain
shigella
flexneri
listeria
monocytogen
use
purpos
classic
vaccin
applic
prophylact
prevent
infecti
diseas
develop
besid
prophylact
applic
vaccin
may
use
treat
alreadi
establish
diseas
infecti
diseas
cancer
inflammatori
disord
although
develop
therapeut
vaccin
still
infanc
especi
field
cancer
vaccin
insight
develop
rapidli
progress
exampl
highlight
cancer
collect
diseas
character
uncontrol
cell
divis
potenti
invad
spread
part
bodi
characterist
caus
gene
mutat
inherit
accumul
life
environment
factor
mutat
may
also
lead
subtl
chang
antigen
repertoir
tumor
cell
compar
healthi
cell
provid
basi
develop
therapeut
cancer
vaccin
aim
induc
specif
cellular
immun
respons
lesser
extent
humor
immun
respons
preestablish
cancer
melief
et
al
van
der
burg
et
al
distinct
made
socal
tumor
eas
largescal
product
poorli
immunogen
man
associ
antigen
present
normal
tissu
express
tumor
neoantigen
newli
form
tumorspecif
antigen
caus
somat
dna
mutat
initi
clinic
trial
cancer
vaccin
focus
use
singl
tumorassoci
antigen
eg
melanomaassoci
prostatespecif
antigen
carcinoembryon
antigen
mixtur
illdefin
antigen
whole
tumor
cell
lysat
whole
tumor
cell
latter
autolog
tumor
cell
directli
isol
patient
allogen
tumor
cell
genet
modifi
express
cytokin
eg
gmcsf
immunestimul
molecul
advantag
use
whole
tumor
cell
presenc
wide
array
tumorspecif
antigen
could
potenti
lead
tumorspecif
immun
respons
disadvantag
illdefin
tumor
cell
lysat
mostli
express
selfantigen
break
immunolog
toler
selfantigen
result
transient
persist
autoimmun
reaction
neoantigen
prefer
use
cancer
vaccin
foreign
protein
sequenc
absent
healthi
tissu
howev
sinc
neoantigen
uniqu
individu
tumor
neoantigen
vaccin
requir
person
approach
vaccin
composit
adjust
patient
need
labor
intens
costli
procedur
must
perform
fast
patient
wait
treatment
variou
neoantigen
vaccin
platform
enter
clinic
treatment
variou
cancer
synthet
long
peptid
slp
vaccin
consist
set
peptid
contain
th
ctl
neoepitop
need
process
profession
apc
cross
present
mhc
class
order
elicit
antigenspecif
cellular
respons
advantag
slp
synthet
peptid
epitop
directli
bind
mhc
class
molecul
need
antigen
process
prevent
tcell
anergi
sinc
length
peptid
synthes
technic
limit
multipl
slp
need
manufactur
separ
combin
cover
breadth
neoantigen
identifi
per
individu
slp
vaccin
success
appli
therapeut
vaccin
treat
cervic
cancer
well
melanoma
ott
et
al
neoantigen
also
deliv
nucleic
acid
dna
mrna
advantag
approach
intrins
adjuv
properti
bacteriallyderiv
plasmid
dna
mrna
eas
multipl
epitop
combin
singl
construct
addit
endogen
express
antigen
lead
effici
mhc
class
present
subsequ
tcell
induct
slpand
nucleic
acidbas
approach
also
use
applic
ex
vivo
set
patientderiv
dc
load
antigen
sourc
stimul
cytokin
administ
patient
see
also
chap
overal
result
neoantigen
vaccin
look
promis
report
partial
complet
cancer
regress
sever
trial
besid
prevent
infecti
diseas
treatment
cancer
vaccin
also
develop
therapeut
applic
includ
treatment
alzheim
diseas
induct
toler
food
compon
prevent
drug
abus
vaccin
still
experiment
phase
develop
highlight
vaccin
design
induc
immunolog
toler
via
gener
regulatori
tcell
treg
aim
durabl
suppress
undesir
immun
respons
exampl
patient
autoimmun
diseas
immun
system
attack
selfantigen
caus
irrevers
damag
tissu
cell
would
benefit
vaccin
could
specif
induc
toler
selfantigen
multipl
sclerosi
selfantigen
known
sever
vaccin
approach
follow
induc
toler
rang
inject
tcell
epitop
deriv
selfantigen
vaccin
tolerogen
nanoparticl
contain
selfantigen
immunosuppress
drug
hunter
et
al
northrup
et
al
similarli
administr
low
dose
antigen
also
call
allergyspecif
immunotherapi
desensit
food
eg
shrimp
peanut
cow
milk
eg
birch
pollen
hous
dust
mite
allergi
appli
shamji
durham
bere
et
al
although
mechan
desensit
remain
larg
unknown
treg
probabl
play
import
role
vaccin
alzheim
diseas
alzheim
diseas
neurodegen
diseas
character
amyloid
plaqu
format
brain
caus
aggreg
cleavag
product
amyloid
precursor
protein
well
protein
vaccin
induc
antibodi
aggreg
form
microtubuleassoci
protein
tau
test
clinic
trial
initi
trial
suffer
seriou
side
effect
due
tcell
activ
later
trial
circumv
problem
show
good
safeti
profil
novak
et
al
studi
learn
antibodi
respons
play
role
slow
diseas
progress
howev
immunolog
alzheim
diseas
complex
far
understood
dansokho
et
al
also
may
difficult
revers
damag
caus
plaqu
format
vaccin
therefor
earli
diagnosi
treatment
patient
alzheim
diseas
import
immunolog
respons
vaccin
depend
rout
administr
current
vaccin
administ
intramuscularli
subcutan
parenter
immun
defin
administr
via
rout
convent
hypoderm
needl
use
usual
induc
system
immun
disadvantag
compar
rout
eg
needl
phobia
infect
caus
needlestick
injuri
needl
reus
requir
vaccin
steril
inject
skill
moreov
parenter
administ
vaccin
gener
result
effect
immun
respons
mucos
surfac
mucos
surfac
common
port
entri
mani
pathogen
induct
mucos
secretori
iga
respons
may
prevent
attach
entri
pathogen
host
exampl
antibodi
cholera
need
gut
lumen
inhibit
adher
colon
intestin
wall
therefor
mucos
eg
oral
intranas
intravagin
immun
may
prefer
may
induc
mucos
system
immun
instanc
oral
administ
live
attenu
salmonella
typhi
vaccin
invad
mucos
line
gut
also
infect
cell
phagocyt
system
throughout
bodi
therebi
stimul
product
secretori
system
antibodi
addit
advantag
mucos
immun
eas
administr
avoid
system
side
effect
czerkinski
holmgren
holmgren
czerkinski
receiv
perspect
oral
deliveri
vaccin
would
prefer
mani
case
vaccine
friendli
howev
limit
number
oral
vaccin
eg
oral
polio
cholera
typhoid
fever
rotaviru
vaccin
made
market
vaccin
base
attenu
version
pathogen
rout
administr
natur
rout
infect
gut
rel
immun
toler
prevent
immun
respons
food
antigen
therefor
rel
high
dose
antigen
requir
induc
signific
respons
replic
vaccin
provid
easili
inactiv
vaccin
addit
oral
bioavail
usual
low
degrad
protein
antigen
gastrointestin
gi
tract
poor
permeabl
wall
gi
tract
case
passiv
transport
process
still
categori
oral
vaccin
abovement
hurdl
degrad
permeat
necessarili
prohibit
oral
immun
small
fraction
antigen
reach
target
site
elicit
immun
respons
target
cell
lymphocyt
antigenpres
accessori
cell
locat
peyer
patch
fig
blymphocyt
popul
includ
cell
produc
secretori
iga
antibodi
peyer
patch
macroscop
identifi
follicular
structur
locat
wall
gastrointestin
tract
peyer
patch
overlaid
microfold
cell
separ
lumin
content
lymphocyt
cell
littl
lysosom
degrad
capac
special
uptak
particul
matter
allow
antigen
sampl
deliveri
underli
apc
moreov
densiti
mucusproduc
goblet
cell
lower
peyer
patch
surround
part
gi
tract
reduc
mucu
product
facilit
access
cell
surfac
lumin
content
particular
import
uptak
nanoand
microparticl
base
vaccin
consequ
attempt
improv
antigen
deliveri
via
peyer
patch
enhanc
immun
respons
made
use
microspher
liposom
modifi
live
vector
attenu
bacteria
virus
vela
ramirez
et
al
latter
addit
advantag
replic
induc
dose
increas
apart
oral
rout
nose
lung
rectum
oral
caviti
skin
select
potenti
site
noninvas
vaccin
administr
vaccin
administ
via
rout
still
develop
besid
mucos
vaccin
number
intraderm
vaccin
deliveri
system
develop
includ
needlefre
jet
inject
vaccin
liquid
form
intraderm
deliveri
microneedl
kersten
hirschberg
van
der
maaden
et
al
hogan
et
al
product
yet
regist
although
influenza
vaccin
given
intramuscularli
fluid
jet
injector
licens
us
intraderm
jet
injector
clinic
develop
eg
inactiv
polio
vaccin
classic
liquid
jet
injector
deliv
small
volum
microlit
rang
liquid
vaccin
formul
high
veloc
depend
fluid
veloc
nozzl
design
vaccin
deposit
intraderm
dispers
deeper
ie
subcutan
intramuscularli
current
version
use
prefil
dispos
deliveri
unit
singl
use
avoid
contamin
anoth
attract
potenti
pain
free
approach
intraderm
vaccin
deliveri
use
microneedl
microneedl
array
small
individu
needl
rang
multipl
microneedl
type
format
solid
microneedl
array
vaccin
compon
coat
hollow
microneedl
liquid
vaccin
formul
deliv
via
micropump
syring
dissolv
microneedl
contain
antigenadjuv
embed
eg
sugar
polym
matrix
dissolv
rapidli
applic
mitragotri
ki
et
al
van
der
maaden
et
al
exampl
shown
fig
except
synthet
peptid
antigen
compon
vaccin
deriv
microorgan
anim
cell
optim
express
requir
vaccin
compon
microorgan
anim
cell
genet
modifi
anim
cell
use
cultiv
virus
product
subunit
vaccin
compon
advantag
vaccin
compon
releas
cultur
medium
howev
virus
caus
cell
lysi
consequ
cultur
medium
contain
high
concentr
host
cell
protein
host
cell
dna
requir
extens
purif
step
three
stage
discern
manufactur
cellderiv
vaccin
cultiv
upstream
process
purif
downstream
process
formul
first
two
stage
reader
refer
chap
formul
biopharmaceut
address
chap
follow
section
deal
formul
aspect
specif
relat
vaccin
formul
vaccin
one
major
determin
influenc
type
immun
respons
elicit
determin
type
costimulatori
molecul
cytokin
express
apc
variou
prr
apc
less
capabl
sens
type
vaccin
encount
determin
set
costimulatori
signal
proinflammatori
cytokin
apc
gener
present
antigen
tcell
peripher
lymphoid
organ
pulendran
ahm
instanc
pathogen
vaccin
contain
lipoprotein
peptidoglycan
trigger
dc
via
predominantli
gener
respons
wherea
stimul
dc
known
yield
robust
ctl
respons
therefor
vaccin
formul
way
appropri
tcell
respons
trigger
done
present
antigen
nativ
format
case
liveattenu
vaccin
formul
nativ
antigen
adjuv
stimul
desir
respons
besid
immun
stimulatori
molecul
vehicl
deliv
antigen
antigen
present
cell
bcell
may
crucial
especi
highli
purifi
subunit
antigen
immun
stimulatori
molecul
deliveri
system
call
adjuv
adjuv
defin
materi
increas
modul
immun
respons
antigen
adjuv
stimul
immun
system
sever
mutual
exclus
mechan
guy
depot
effect
lead
slow
antigen
releas
prolong
antigen
present
attract
stimul
apc
local
tissu
damag
bind
prr
present
apc
deliveri
antigen
region
lymph
node
improv
antigen
uptak
transport
present
apc
colloid
aluminum
salt
hydroxid
phosphat
wide
use
adjuv
mani
classic
vaccin
formul
adjuv
eg
monophosphoryl
lipid
hpv
vaccin
oilinwat
emuls
influenza
vaccin
introduc
market
vaccin
moreov
numer
adjuv
sever
stage
pre
clinic
test
use
veterinari
vaccin
tabl
show
exampl
wellknown
adjuv
sinc
oral
immun
possibl
avail
vaccin
see
section
rout
administr
strategi
mix
individu
vaccin
order
limit
number
inject
common
practic
sinc
mani
decad
current
vaccin
avail
contain
six
nonrel
antigen
diphtheriatetanuspertussishepat
bpoliohaemophilu
influenza
type
b
vaccin
anoth
exampl
mmr
vaccin
alon
combin
varicella
vaccin
sometim
vaccin
contain
antigen
sever
subtyp
particular
pathogen
pneumococc
conjug
vaccin
exampl
vaccin
contain
polysaccharid
pneumococc
strain
conjug
carrier
protein
provid
thelper
cell
recognit
result
induc
immunolog
memori
combin
vaccin
compon
sometim
result
pharmaceut
well
immunolog
problem
instanc
formaldehydecontain
compon
may
chemic
react
compon
unstabl
antigen
may
need
freez
dri
wherea
antigen
frozen
compon
compat
mix
prior
inject
shortterm
incompat
end
dualchamb
cartridg
cf
chap
develop
immunolog
point
view
immun
schedul
individu
compon
combin
vaccin
match
pertussi
vaccin
instanc
given
earli
life
possi
amorij
et
al
ble
sinc
whoop
cough
danger
young
children
wherea
hepat
b
vaccin
given
later
life
mainli
sexual
transmit
diseas
even
condit
match
immun
schedul
met
compon
pharmaceut
compat
success
combin
vaccin
warrant
vaccin
compon
combin
vaccin
may
exhibit
differ
behavior
vivo
compar
separ
administr
compon
instanc
enhanc
paradiso
et
al
well
suppress
mallet
et
al
humor
immun
respons
report
modern
vaccin
meet
similar
standard
biotechnolog
pharmaceut
character
combin
appropri
biochem
physicochem
immunochem
techniqu
cf
chap
use
stateofth
art
analyt
techniqu
design
releas
new
vaccin
gain
import
current
anim
experi
need
qualiti
control
mani
vaccin
vitro
analyt
techniqu
may
eventu
partli
substitut
test
vivo
develop
product
process
vaccin
compon
combin
suitabl
assay
defin
assay
subsequ
appli
routin
product
column
chromatograph
hplc
electrophoret
techniqu
gel
electrophoresi
capillari
electrophoresi
provid
inform
puriti
molecular
weight
physicochem
properti
antigen
physicochem
assay
compris
mass
spectrometri
spectroscopi
includ
circular
dichroism
fluoresc
spectroscopi
inform
obtain
mainli
molecular
weight
conform
antigen
immunochem
assay
enzymelink
immunoassay
power
method
quantif
antigen
use
monoclon
antibodi
prefer
specif
protect
human
antibodi
inform
obtain
conform
access
epitop
antibodi
direct
moreov
use
biosensor
make
possibl
measur
antigenantibodi
interact
momentarili
allow
accur
determin
bind
kinet
affin
constant
furthermor
sinc
practic
vaccin
particul
natur
sensibl
use
stateoftheart
particl
size
count
method
character
jiskoot
depend
specif
characterist
vaccin
store
solut
freezedri
formul
usual
shelf
life
depend
composit
physicochem
characterist
vaccin
formul
storag
condit
typic
order
sever
year
qualiti
primari
contain
influenc
longterm
stabil
vaccin
eg
adsorpt
ph
chang
result
contact
vial
wall
vial
stopper
use
ph
indic
temperatureor
timesensit
label
vial
vaccin
monitor
chang
color
long
expos
high
temperatur
avoid
unintent
administr
inappropri
store
vaccin
despit
tremend
success
classic
vaccin
still
mani
infecti
diseas
diseas
eg
cancer
effect
vaccin
exist
although
modern
vaccineslik
biopharmaceuticalsar
expens
calcul
may
indic
costeffect
vaccin
mani
diseas
addit
grow
resist
exist
arsen
antibiot
increas
need
develop
vaccin
common
bacteri
infect
expect
novel
vaccin
sever
diseas
becom
avail
case
prefer
type
vaccin
chosen
one
differ
option
describ
chapter
imagin
three
vaccin
type
viral
diseas
formaldehyd
inactiv
viru
genet
attenu
live
viru
highli
purifi
viral
protein
one
vaccin
supplement
adjuv
adjuv
b
three
vaccin
contain
ad
adjuv
c
vaccin
almost
antigen
composit
despit
one
vaccin
given
consider
lower
dose
one
induc
level
protect
one
vaccin
abl
induc
cellular
cytotox
tcell
respons
antibodi
prevent
infect
diseas
immun
system
prevent
unwant
tcell
respons
selfantigen
affect
vaccin
design
definit
subunit
vaccin
give
three
differ
type
subunit
vaccin
mention
least
three
advantag
three
disadvantag
nucleic
acid
vaccin
give
one
advan
